Semanteon Capital Management LP Takes $274,000 Position in Insulet Corporation $PODD

Semanteon Capital Management LP purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 872 shares of the medical instruments supplier’s stock, valued at approximately $274,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC increased its position in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet during the first quarter worth approximately $26,000. SouthState Corp lifted its stake in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. purchased a new position in shares of Insulet during the second quarter worth approximately $32,000. Finally, Golden State Wealth Management LLC increased its holdings in shares of Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 69 shares during the period.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on PODD. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Barclays upped their price target on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Wells Fargo & Company lifted their price objective on shares of Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Jefferies Financial Group raised their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Truist Financial boosted their price target on shares of Insulet from $365.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $374.10.

Insulet Stock Performance

NASDAQ:PODD opened at $332.70 on Monday. The firm’s fifty day simple moving average is $323.58 and its 200-day simple moving average is $312.88. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $23.40 billion, a PE ratio of 101.12, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $353.50.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same quarter in the previous year, the firm earned $1.08 earnings per share. The firm’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.